IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Tenax Therapeutics Inc

CUSIP: 88032L900 | 3 institutional holders

Quarters

Q2 2017Q1 2017Q4 2016Q3 2016Q2 2016
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile